Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP-100
- Development stage
- Phase 2
- Lead developer
- Esperance Pharmaceuticals
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
EP-100 is a synthetic targeted membrane-disrupting peptide (tMDP) designed to selectively seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors on their surfaces. It consists of a 28-amino acid LHRH peptide conjugated to an 18-amino acid cytolytic peptide. The drug binds directly to the extracellular LHRH receptor, which is overexpressed in various cancers such as ovarian, breast, colon, and uterine cancers. Upon binding, the cytolytic portion disrupts the cell membrane, leading to rapid tumor cell death by necrosis. Preclinical studies have shown synergy between EP-100 and chemotherapeutic agents like paclitaxel. Clinical trials have demonstrated its safety profile and potential efficacy in patients with advanced solid tumors expressing LHRH receptors, particularly those with ovarian cancer resistant to standard therapies[1][2][3][5].
- Brand names
- EP-100EP100EP 100
- Other names
- LHRH-Phor21LHRH-Phor-21LHRH-Phor 21LHRH-lytic peptide conjugate
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on EP-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP-100.